UroEdge™
PET Imaging Learning Center
Positron Emission Tomography (PET) is an advanced molecular imaging technique that uses specialized radiotracers to visualize biological processes within the body. In oncology, PET imaging plays a vital role in cancer detection, staging, treatment selection, response assessment, and disease monitoring, supporting more informed clinical decision-making across a wide range of malignancies. Our associated physicians discuss the importance of imaging in more detail below.
PET Tumor Board
| Title | Speaker | Excerpt | Date | |
|---|---|---|---|---|
| PET Tumor Board: Discordant PSMA and FDG PET Findings in Concurrent Adenocarcinoma and Neuroendocrine Prostate Cancer | E. David Crawford, MD | Experts review a rare case involving the coexistence of metastatic neuroendocrine prostate cancer and recurrent adenocarcinoma with discordant FDG and PSMA PET imaging findings. | 2026-10-06 | 2025 |
| PET Tumor Board: Negative PSMA PET Imaging in Biochemical Recurrence with Incidental Detection of Primary Lung Adenocarcinoma | E. David Crawford, MD | Experts discuss rising PSA despite negative PSMA PET imaging and review how surveillance imaging ultimately identified an early-stage primary lung adenocarcinoma. | 2026-10-06 | 2026 |
| PSMA PET at Low PSA: Managing a Solitary Suspicious Lesion After Radiation and ADT | E. David Crawford, MD | Expert discussion on PSMA PET and early recurrence. | 2026-04-22 | 2025 |
| Interpreting PSMA PET After Prostatectomy: A Case of Missed Recurrence | E. David Crawford, MD | PSMA PET missed recurrence in this case. | 2026-04-20 | 2025 |
| PET Tumor Board: Case 8 – A Case of An 81-year-old Man with High-risk Prostate Cancer with Initial PSA of 8.4 and a Large Peripheral Zone Lesion | E. David Crawford, MD | This multidisciplinary tumor board highlights how PSMA PET identifies recurrent prostate cancer and informs decisions on salvage therapy, radiation, and cryotherapy. | 2025-12-05 | 2025 |
| PET Tumor Board–Case 7: A Case of a 71-year-old with PSA of 6.3, High PSA Density, and a PI-RADS 4 Lesion | E. David Crawford, MD | The Case shows PSMA PET detected clinically significant prostate cancer missed by MRI-guided biopsy. | 2025-11-19 | 2025 |
| PET Tumor Board – Case 6: A Case of a 57-year-old with an Elevated PSA and Small Prostate Volume | E. David Crawford, MD | A 57-year-old with favorable-intermediate risk prostate cancer illustrates PSMA PET/MRI interpretation, rib uptake pitfalls, and treatment selection. | 2025-10-05 | 2025 |
| PET Tumor Board Case 5: A Case of a 77-year-old Prostate Cancer Patient with Ulcerative Colitis and Uncertain PET Findings | E. David Crawford, MD | Multidisciplinary case review shows how PSMA PET false positives can mimic nodal disease and alter prostate cancer management. | 2025-08-18 | 2025 |
| PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5 | E. David Crawford, MD | E. David Crawford, MD, and the panel discuss a case of a 66-year-old with elevated PSA, MRI PIRADS 5 lesion, and PSA density of 0.11. | 2025-08-15 | 2025 |
| PET Tumor Board - Case 3: 62-year-old BRCA2-Positive Prostate Cancer Survivor with PSA Recurrence | E. David Crawford, MD | E. David Crawford, MD, presents a case involving a 62-year-old BRCA2-positive prostate cancer survivor with PSA recurrence. | 2025-08-07 | 2025 |
| PET Tumor Board - Case 2: A Case of a 72-year-old with Rising PSA and MRI Showing PI-RADSv2.1 Categories 4 and 5 | E. David Crawford, MD | E. David Crawford, MD, presents a case involving a 72-year-old with a rising PSA and suspicious MRI findings who initially delays biopsy. | 2025-07-23 | 2025 |
| PET Tumor Board - Case 1: A Case of a 55-year-old Prostate Cancer Survivor with Rising PSA Five Years After Radical Prostatectomy | E. David Crawford, MD | E. David Crawford, MD, presents a case of a 55-year-old prostate cancer survivor with rising PSA five years after radical prostatectomy. | 2025-06-24 | 2025 |
| PET Tumor Board Case 6: Patient with a Strong Family History of PCa | E. David Crawford, MD | In this discussion, E. David Crawford, MD, Jack A. Vickers Director of Prostate Research and Professor of Urology at the University of California, San Diego, leads a discussion of the case study of a 63-year-old patient with a strong family history of prostate cancer. | 2024-08-16 | 2024 |
| PET Tumor Board Case: Gleason Grade 2 PCa After Multiple Treatments for BPH | E. David Crawford, MD | In this discussion, E. David Crawford, MD, Jack A. Vickers Director of Prostate Research and Professor of Urology at the University of California, San Diego, leads a discussion of the case study of a healthy 69-year-old male with a history of multiple BPH treatments presenting with Gleason Grade 2 prostate cancer. | 2024-07-19 | 2024 |
| PET Tumor Board Case 4: Rapid Rise in PSA | E. David Crawford, MD | In this discussion, E. David Crawford, MD, Professor of Urology and Jack A. Vickers Director of Prostate Research at the University of California, San Diego, leads a discussion of the case study of a healthy 80-year-old male with a history of BPH presenting with a rapid rise of PSA from a PSA of 3-4 ng/ml to 9.7 ng/ml and increased urgency and perception of difficulty fully voiding. | 2024-06-25 | 2024 |
| PET Tumor Board Case: Failing ADT and Proton Therapy | E. David Crawford, MD | In this discussion, the third in a trilogy on PSMA PET supported by Blue Earth Diagnostics, E. David Crawford, MD, Editor-in-Chief at Grand Rounds in Urology, leads a discussion of the case study of a 60-year-old male presenting with a PSA of 10.5 ng/ml and a Gleason score of 7 after 6 months of ADT and Proton Therapy. | 2023-12-08 | 2023 |
| PET Tumor Board Case: A 68-Year-Old Male with Rising Prostate-Specific Antigen (PSA) | E. David Crawford, MD | In this discussion, the second in a trilogy on PSMA PET supported by Blue Earth Diagnostics, three experts join E. David Crawford, MD, Editor-in-Chief at Grand Rounds in Urology, to discuss a challenging case study. Dr. Crawford introduces the case study of a 68-year-old male with rising prostate-specific antigen (PSA) levels. | 2023-11-13 | 2023 |
| PET Tumor Board Case: A 71-Year-Old Pulmonologist with Prostate Cancer and Rising Prostate-Specific Antigen (PSA) | E. David Crawford, MD | In this discussion, the first in a trilogy on PSMA PET supported by Blue Earth Diagnostics, three experts join E. David Crawford, MD, Editor-in-Chief at Grand Rounds in Urology, to discuss a challenging case study. Dr. Crawford introduces the case study of a 71-year-old pulmonologist with prostate cancer and rising prostate-specific antigen (PSA) levels to a panel of experts. | 2023-10-18 | 2023 |